-       Report 
- August 2025
-  194 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- August 2025
-  186 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- August 2025
-  182 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- August 2025
-  199 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- August 2025
-  189 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
             -       Report 
- August 2025
-  180 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- August 2025
-  196 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
          -       Report 
- January 2025
-  120 Pages 
- Global 
   From       €5295EUR$5,950USD£4,661GBP 
          -       Report 
- October 2024
-  120 Pages 
- Global 
   From       €5295EUR$5,950USD£4,661GBP 
            -       Report 
- October 2025
-  193 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- August 2025
-  198 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- August 2025
-  190 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- August 2025
-  188 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
          -       Report 
- October 2025
-  369 Pages 
- Global 
   From       €5206EUR$5,850USD£4,582GBP 
          -       Report 
- October 2025
-  194 Pages 
- Global 
   From       €5206EUR$5,850USD£4,582GBP 
          -       Report 
- October 2025
-  193 Pages 
- Global 
   From       €5206EUR$5,850USD£4,582GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €3995EUR$4,490USD£3,517GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €3995EUR$4,490USD£3,517GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €3995EUR$4,490USD£3,517GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €3995EUR$4,490USD£3,517GBP 
       
      Sevoflurane is an anesthetic drug used in medical procedures to induce and maintain general anesthesia. It is a volatile anesthetic, meaning it is administered as a gas and is rapidly eliminated from the body. It is a halogenated ether, meaning it contains a halogen atom, such as fluorine, bonded to an ether molecule. It is a colorless, non-flammable liquid with a pleasant odor. It is commonly used in pediatric and adult patients for induction and maintenance of general anesthesia. It is also used    in combination with other anesthetic drugs to provide balanced anesthesia.
Sevoflurane is a popular anesthetic drug due to its rapid onset and offset of action, low blood solubility, and low risk of toxicity. It is also relatively inexpensive compared to other anesthetic drugs.
Some companies in the sevoflurane market include Baxter International, AbbVie, Merck & Co., and Hospira. Show Less   Read more